Board summary
Key figures
35,742
Registered population
59.8% aged 18–64
21.6%
Aged 65+
ICB 14.9% · England 17.9%
11.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~3,949
Core20 residents (est.)
Resident basis; registered basis ~4,231 · see page 3
7,350
Hypertension register
+10.11% in 3 yrs · England +5.60%
303
SMI register
8.5% of Wigan (LAD)'s
952
COPD register
Reviews -0.75% in 3 yrs
Forecast to 2030
8,971
Hypertension patients, 2030
+1,621 on today
73.2%
QRISK ≥20% on statins, 2030
+2.09pp over 3 yrs
4.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Eighteen of 25 three-year trends trail England.
Trailing changes include asthma reviews (-0.9% vs England +4.4%; 701 unreviewed scale indicator) and statins in diabetes with CVD (-1.0% vs England +1.0%).
Strong current chronic disease control and reviews.
Registered achievement exceeds England in hypertension treated to target (77.2% vs 70.3%), COPD reviews (87.0% vs 76.4%), and heart failure reviews (88.5% vs 78.5%).
Population, age and ethnicity
Patients aged 65+ represent 21.6% of the list, exceeding Wigan and England averages
Swan Network Wigan PCN serves 35,742 registered patients across its practices. Patients aged 65+ make up 21.6% (7,731), above Wigan (18.8%), NHS Greater Manchester ICB (14.9%), and England (17.9%). Children aged 0–17 represent 18.5% (6,625), below Wigan (20.0%), the ICB (21.8%), and England (19.6%). Projected list growth to 2030 is 0.3% under an unverified projection methodology (Wigan 1.1%, ICB 1.6%, England 2.3%). Recorded Gypsy or Irish Traveller and Roma groups each represent 0.1% of residents. Primary care planning must account for an older demographic, although registered counts lack supplied observation periods and ethnicity uses Census data.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 66.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is below England but spans 18.6 pp across member practices
The PCN Core20 share is 11.6% (average IMD decile 6.0), below Wigan (LAD) at 29.4%, the ICB at 40.7%, and England at 21.0%. The weighted practice share is 11.8%, while resident deciles 1 and 2 counts total 3,949. Across practices, the Core20 range is 18.6 pp. South Wigan Medical Practice records 18.58% (1,208 estimated patients), Kumar Family Practice records 15.58% (808), Marus Bridge Practice records 14.88% (806), and Saxena L records 0.0%. Targeted outreach should focus on these three practices where Core20 volume concentrates.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
303
SMI register
0.85% recorded prevalence
206
Learning disability register
0.58% recorded prevalence
8
Care homes, 372 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
Recorded learning disability prevalence is 0.6% (206 patients), below Wigan (0.7%) and matching the ICB (0.6%) and England (0.6%). Severe mental illness prevalence is 0.8% (303 patients), below Wigan (1.0%), the ICB (1.1%), and England (1.0%). The PCN catchment includes 8 care homes with 372 beds, though resident registrations are unconfirmed. Lower recorded prevalence on crude registers does not establish under-detection or unmet need.
Severe mental illness: physical health checks
Recorded severe mental illness prevalence is 0.8% (England 1.0%). Annual checks reach 92.0% for blood pressure (England 83.4%) and 92.0% for BMI (England 82.1%). Smoking cessation offers for qualifying conditions fell 2.5 pp (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,350
Hypertension register
+10.11%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+1.66pp
BP control, under 80
≤140/90 · +1.17pp aged 80+
+1,621
More patients by 2030
Forecast 8,971 (25.05%)
Hypertension case-finding and control
Hypertension prevalence is 20.7% (7,350 patients), above Wigan (18.0%), NHS Greater Manchester ICB (14.4%), and England (15.2%), with three-year growth of +10.1% (England +5.6%). Clinical control remains high: 77.2% of hypertensive patients are treated to target versus 75.6% in Wigan, 71.4% in the ICB, and 70.3% in England. However, the three-year change in blood pressure control for patients aged under 80 was +2.2%, trailing Wigan (+6.2%), the ICB (+3.6%), and England (+3.2%). While blood pressure control currently exceeds comparators, trailing three-year progress indicates that proactive recall could be prioritised to sustain management as the register expands.
Lipids and statins
For patients with diabetes and CVD, statin coverage is 83.7%, below Wigan (84.6%), NHS Greater Manchester ICB (85.8%), and England (84.4%), following a -1.0% three-year change (England +1.0%). Lagging secondary prevention statin coverage against comparators suggests a targeted review of diabetic patients with cardiovascular disease could be prioritised to close treatment gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 67,720 | £2.50 | £1.94 | £1.86 | £169,300 |
| Cardiovascular (all), 2025 | 86,691 | £5.63 | £3.15 | £3.33 | £488,070 |
Lipid-regulating drugs (2026) cost £2.50 per item across 67,720 prescribed items, exceeding Wigan (£2.09), NHS Greater Manchester ICB (£1.94), and England (£1.86), or £43,341 more than at England's unit cost. Higher unit costs than comparators may reflect product choice or formulary mix, which a local prescribing audit could verify.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.94%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.98%
Asthma prevalence, PCN 3-yr % change
Recorded asthma prevalence is 8.6% (2,899 patients; England 6.6%) and COPD prevalence is 2.7% (952 patients; England 1.9%). Annual review rates exceed England for asthma (75.8% vs 65.7%) and COPD (87.0% vs 76.4%), though three-year changes were -0.9% (England +4.4%) and -0.8% (England +2.8%). A scale indicator estimates 701 asthma patients without a recorded review across the register. Asthma prescribing was 1,831 items per 1,000 aged 5–19 (England 1,488).
Cancer register and children's immunisation
Cancer QOF prevalence (all ages) is 3.9%, compared with 4.0% in Wigan (LAD), 3.3% in NHS Greater Manchester ICB, and 3.8% in England. Crude recorded prevalence does not establish undiagnosed disease or coding variation.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB (2022), 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, in line with England (55.3%) but at a distance of -19.4 pp to the 75.0% national ambition by 2028. Known-stage share was 70.8% (11,679 of 16,492 registered cancers). Sizing the gap to 75.0% indicates about 2,270 extra early diagnoses annually. System staging reflects ICB diagnostic pathways rather than PCN performance. Although PCN cervical screening reached 79.1% (England 66.8%), three-year coverage fell 1.9% (England -1.0%). Primary care coordination supports screening uptake.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For cancer waiting times (Jul 2026 (provisional)), Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust achieved 76.8% on the 62-day referral-to-treatment standard, with a distance of -8.2 pp to the 85.0% standard. This was behind North Cheshire and Mersey NHS Foundation Trust (83.7%) and Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), but above NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). On the 28-day faster diagnosis standard, Wrightington, Wigan and Leigh reached 82.8% (standard 75.0%), exceeding the ICB (79.5%) and England (79.3%). These trust metrics describe provider pathways rather than PCN performance.
| Pathways within standard (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | North Cheshire and Mersey | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.80 | 72.39 | 80.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 89.04 | 95.46 | 98.17 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.78 | 77.96 | 83.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 0.49 | 14.04 | 0.53 | 21.40 |
| CT | 7.78 | 13.08 | 2.32 | 9.92 |
| Echocardiography | 24.37 | 34.88 | 28.04 | 28.48 |
| Colonoscopy | 6.10 | 18.04 | 15.98 | 30.83 |
| Gastroscopy | 12.54 | 18.17 | 20.24 | 29.02 |
| All 15 DM01 tests | 14.36 | 21.17 | 6.34 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In the Community Services Dataset (Jun 2026 (provisional)), adults aged 65+ accounted for 58.5% of borough residents' community contacts (28,190 of 48,150 total contacts). Activity is reported at local authority level rather than PCN level. With 21.6% of PCN patients aged 65+, coordination between primary care and community teams supports chronic disease and older-age care pathways.
Practice variation and patient experience
Ease of phone contact varies by 34.7 pp across network practices
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Zaman | 84 | 12.6 | 98.6% | 88.3% | 99.3% |
| South Wigan | 105 | 18.6 | 89.4% | 69.5% | 96.2% |
| Bryn Cross Surgery | 97 | 10.1 | 93.0% | 74.9% | 95.2% |
| Marus Bridge | 118 | 14.9 | 70.1% | 71.2% | 91.3% |
| Saxena L | 112 | 0.0 | 89.4% | 74.1% | 88.6% |
| Kumar | 96 | 15.6 | 63.9% | 74.0% | 87.7% |
| Medicentre | 120 | 5.5 | 68.5% | 64.2% | 80.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eighteen of 25 three-year trends trail England despite high current clinical baselines
Across 25 tracked measures, 18 three-year trends trail England. Heart failure annual reviews rose +1.0% from 2023 to 2025, behind England (+8.7%) and Wigan (+3.9%), while the recorded review rate is 88.5% (England 78.5%; ICB 80.0%). Similarly, smoking cessation offers fell 2.5 pp from 2023 to 2025 (England +0.1 pp), with recorded achievement at 96.0% (England 94.2%). Conversely, diabetes HbA1c control without frailty rose +19.6% (England +4.4%; ICB +6.2%) to 66.0% (England 57.4%). Slower trajectory against England may reflect high starting baselines, though this requires ongoing monitoring.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
QRISK statin treatment
COPD register
Diabetes HbA1c control
Diabetes statin (no CVD)
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (372 beds) | n/a | Schools (catchment) | 41 | n/a |
| Children's centres | 3 | 20 | Places of worship | 27 | 164 |
| Libraries | n/a | 10 | Primary schools (LA maintained) | 8 | 68 |
| Primary academies | 5 | 21 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Targeted Core20 recall and outreach
Core20 share spans 18.6 pp across practices (PCN 11.6% vs England 21.0%), from 0.0% at Saxena L to 18.58% (1,208 estimated patients) at South Wigan Medical Practice. For discussion: the PCN could prioritise proactive recall and tailored outreach at the practices with the highest Core20 share and volume. Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Option 2
Asthma annual review recall audit
Asthma reviews fell 0.9% over three years (England +4.4%; Wigan +0.9%), with a scale indicator of 701 patients without a recorded review out of 2,899 register patients (75.8% vs England 65.7%). For discussion: practices could run a structured asthma recall and inhaler check using a standardised review template. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Practice telephone access workflow review
Ease of phone contact spans 34.7 pp across practices in the 2026 survey, from 63.9% at Kumar Family Practice to 98.6% at Zaman (England 56.9%; response rates 23.9% to 27.8%). For discussion: practices could review peak call-handling capacity, triage routing, and shared access protocols starting where phone ratings are lowest. Moderate effort to run.
Evidence base: patient-reported access and experience is the demand-side signal on primary-care capacity and access model; practices with sustained poor experience are the ones to prioritise for access-model support.
Policy anchor: 10 Year Health Plan, shift from hospital to community (Neighbourhood Health Service).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory frailty care (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension review audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Targeted Core20 recall and outreach (p12) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN & Practice |
| Option 2 · Asthma annual review recall audit (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Practice telephone access workflow review (p12) | GPPS easy to contact the practice by phone · GPPS survey response rate | 10YHP, hospital to community | Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
